Skip to main content

Security report for adrxpharma.com

ADRx, Inc. · Healthcare · United States

Medium risk. 7 critical or high findings in Email security, Security headers and 2 other checks.

Security score

65/100

Risk levelMedium

0–100, higher is better. How it is calculated

ADRx, Inc. is a small healthcare-focused biotechnology company specializing in innovative drug discovery, particularly in developing small molecule therapies targeting neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's Disease. The company leverages structure-based design to disrupt protein aggregation diseases, positioning itself as a pioneer in this niche market. Their website is professionally designed using the Wix platform, providing clear business and contact information but lacks comprehensive privacy and security policy disclosures. Technically, the site uses modern web technologies and is moderately optimized for performance and accessibility. Security posture is adequate with HTTPS enforced but could benefit from enhanced security headers and incident response information. The absence of WHOIS registration data raises concerns about domain legitimacy, which impacts overall trustworthiness. Strategic recommendations include improving privacy compliance, adding security policies, and verifying domain registration to enhance credibility and trust.

Scanned

NIS2 and GDPR posture

GDPR outside view
50/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

7 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  3. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Privacy Policy found

      GDPR requires a clear and accessible privacy policy

      What to do: Add a comprehensive privacy policy page and link to it prominently

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

Need hands-on remediation? Email guard@offseq.com

Keep watching adrxpharma.com

This scan found 24 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
35
Email security
60
DNS health
75
Network security
100
GDPR outside view
50
Average
65

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

ADRx operates in the competitive biotechnology sector with a focus on neurodegenerative disease therapeutics. Their pioneering use of structure-based drug design provides a competitive advantage. The business model centers on research and development of novel small molecule drugs, targeting a specialized audience of pharmaceutical partners, researchers, and investors. The company maintains a professional online presence but lacks visible partnerships or subsidiaries. Growth indicators are not explicitly stated, and no parent company or subsidiaries are identified. The company’s contact details and physical address in California support its legitimacy, though domain registration inconsistencies warrant further investigation.

Security posture

The website demonstrates a basic to moderate security maturity level with HTTPS enabled and no obvious vulnerabilities detected in the frontend code. However, the lack of security headers, absence of incident response contacts, and missing vulnerability disclosure policies indicate gaps in security best practices. There is no evidence of GDPR compliance or data protection officer contact information, which may be a compliance risk depending on their user base. The site uses Wix’s standard scripts and analytics, which are generally secure but require regular audits. Overall, the security posture is functional but could be significantly improved with policy disclosures and enhanced technical controls.

Recommendations

  1. Register the domain properly and ensure WHOIS data is publicly available to improve legitimacy and trust.
  2. Publish comprehensive privacy and cookie policies to comply with GDPR and other privacy regulations.
  3. Implement security headers such as Content-Security-Policy, X-Frame-Options, and Strict-Transport-Security.
  4. Add a security incident response page with contact information for reporting vulnerabilities or abuse.
  5. Enhance website accessibility and SEO features to improve user experience and search engine ranking.

Contact details published on the site

Addresses
Legal name
ADRx, Inc.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
ADRx, Inc.
Description
ADRx is an innovative drug discovery company focused on transforming atomic structures into small molecule therapies to treat neurodegenerative diseases such as Alzheimer’s, ALS, and Parkinson’s Disease. They apply structure-based design to disrupt protein aggregation diseases and develop therapeutics targeting patient-derived pathological protein structures.
Key services
Structure-based drug design, Therapeutic development for neurodegenerative diseases, Discovery of small molecule modulators of pathological protein interactions
Content quality
good
Branding
consistent

Technology

Stack
Wix.com Website Builder, JavaScript, Webpack, Core-js polyfills
Frameworks
Wix Thunderbolt
Platforms
Wix
Performance
moderate
Mobile
basic
Accessibility
basic
SEO
basic

Security

Observed score
70/100
Good practices seen
  • HTTPS enforced

Analytics and tracking

Services
Wix FedOps
Tracking level
minimal
Privacy practices
poor

Advertising

Transparency
poor

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
moderate

Key observations

  1. Website is fully accessible with no blocking or WAF challenge.
  2. WHOIS data is missing or domain is unregistered, which is unusual for an active business website.
  3. No privacy, cookie, or terms of service policies found on the site.
  4. Contact information is clearly provided including email, phone, and physical address.
  5. Website uses Wix platform with standard Wix scripts and assets.
  6. No social media links detected on the homepage.
  7. No security incident response or vulnerability disclosure information present.
  8. Content is focused on healthcare drug discovery with no adult or questionable content.
  9. SEO and accessibility features are basic but present.
  10. No advertising or tracking pixels detected beyond Wix FedOps analytics.
Technical notes

Notes

The website is built on the Wix platform using Wix Thunderbolt framework and standard JavaScript libraries. It employs modern web technologies including Webpack and polyfills for compatibility. Hosting is provided by Wix, ensuring reliable uptime and HTTPS support. Performance is moderate with room for optimization, especially in mobile responsiveness and accessibility. The site lacks advanced SEO optimizations and comprehensive metadata beyond basic Open Graph and JSON-LD structured data. No third-party advertising or tracking services beyond Wix FedOps analytics are detected, minimizing privacy risks. Technical debt appears low, but improvements in security headers and policy disclosures are recommended to reduce risk.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with adrxpharma.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review adrxpharma.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.